Speech, Language and Non-verbal Communication in CLN2 and CLN3 Batten Disease

被引:0
|
作者
Morison, Lottie D. [1 ,2 ]
Whiteman, Ineka T. [3 ,4 ,5 ]
Vogel, Adam P. [2 ,6 ]
Tilbrook, Lisa [3 ,7 ]
Fahey, Michael C. [3 ,8 ,9 ]
Braden, Ruth [1 ,2 ]
Bredebusch, Joanna [2 ]
Hildebrand, Michael S. [10 ,11 ]
Scheffer, Ingrid E. [3 ,10 ,11 ,12 ,13 ,14 ]
Morgan, Angela T. [1 ,2 ,3 ,12 ]
机构
[1] Murdoch Childrens Res Inst, Speech & Language, Parkville, Vic, Australia
[2] Univ Melbourne, Dept Audiol & Speech Pathol, Parkville, Vic, Australia
[3] Batten Dis Support & Res Assoc BDSRA Australia, Shelley Beach, Qld, Australia
[4] Batten Dis Support Res & Advocacy Assoc, Columbus, OH USA
[5] Batten Dis Fdn, Austin, TX 78757 USA
[6] Redenlab Pty Ltd, Melbourne, Vic, Australia
[7] Port Pirie Hosp, Port Pirie, SA, Australia
[8] Monash Univ, Dept Paediat, Clayton, Vic, Australia
[9] Monash Hlth, Clin Sci, Clayton, Vic, Australia
[10] Univ Melbourne, Epilepsy Res Ctr, Heidelberg, Vic, Australia
[11] Austin Hlth, Dept Med, Heidelberg, Vic, Australia
[12] Royal Childrens Hosp, Dept Paediat, Parkville, Vic, Australia
[13] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia
[14] Murdoch Childrens Res Inst, Neurosci Res Grp, Melbourne, Vic, Australia
基金
英国医学研究理事会;
关键词
Batten disease; cerliponase alfa; CLN2; CLN3; enzyme replacement therapy; language; neuronal ceroid lipofuscinoses; speech; NEURONAL CEROID-LIPOFUSCINOSIS; RATING-SCALE; CHILDREN; MUTATIONS; RELIABILITY; PHENOTYPE; SYMPTOMS; FEATURES; DECLINE; SKILLS;
D O I
10.1002/jimd.12838
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CLN2 and CLN3 diseases, the most common types of Batten disease (also known as neuronal ceroid lipofuscinosis), are childhood dementias associated with progressive loss of speech, language and feeding skills. Here we delineate speech, language, non-verbal communication and feeding phenotypes in 33 individuals (19 females) with a median age of 9.5 years (range 3-28 years); 16 had CLN2 and 17 CLN3 disease; 8/15 (53%) participants with CLN2 and 8/17 (47%) participants with CLN3 disease had speech and language impairments prior to genetic diagnosis. At the time of study all participants, bar one, had language impairments. The remaining participant with typical language was tested at age 3 years, following pre-symptomatic enzyme replacement therapy (ERT) from age 9 months. CLN2 and CLN3 disease had different profiles. For CLN2 disease, all affected individuals showed language impairment with dysarthria; older individuals with classical disease progressively became non-verbal. For CLN3 disease, the presentation was more heterogeneous. Speech impairment was evident early in the disease course, with dysarthria (13/15, 87%), often manifesting as neurogenic stuttering (5/15, 33%). Participants with CLN2 disease had comparable expressive and receptive language skills (p > 0.99), yet participants with CLN3 disease had stronger expressive language than receptive language skills (p = 0.004). Speech, cognitive and language impairment and adaptive behaviour showed progressive decline in both diseases. Individuals with pre-symptomatic ERT or atypical CLN2 disease were less impaired. Challenging behaviours were common in CLN3 (11/17, 65%), but less frequent in CLN2 (4/16, 25%) disease. Individuals with Batten disease require tailored speech therapy incorporating communication partner training utilising environment adaptations and informal communication behaviours.
引用
收藏
页数:17
相关论文
共 50 条
  • [1] Mitochondrial abnormalities in CLN2 and CLN3 forms of Batten disease
    Dawson, G
    Kilkus, J
    Siakotos, AN
    Singh, I
    MOLECULAR AND CHEMICAL NEUROPATHOLOGY, 1996, 29 (2-3) : 227 - 235
  • [2] Farnesylation of Batten disease CLN3 protein
    Pullarkat, RK
    Morris, GN
    NEUROPEDIATRICS, 1997, 28 (01) : 42 - 44
  • [3] Mutations in CLN3 gene responsible of Batten disease
    Milà, M
    Mallolas, J
    Pineda, M
    Ferrer, I
    Vernet, A
    Badenas, C
    Sánchez, A
    Ballesta, F
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 145 - 145
  • [4] Nature of Batten disease CLN3 protein in brain
    Pullarkat, RK
    Pullarkat, PS
    Morris, GN
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S193 - S193
  • [5] Spectrum of mutations in the Batten disease gene, CLN3
    Munroe, PB
    Mitchison, HM
    ORawe, AM
    Anderson, JW
    Boustany, RM
    Lerner, TJ
    Taschner, PEM
    deVos, N
    Breuning, MH
    Gardiner, RM
    Mole, SE
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (02) : 310 - 316
  • [6] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, M.
    Vierhile, A.
    Vermilion, J.
    Adams, H.
    Zimmerman, G.
    Corre, C.
    Augustine, E.
    Mink, J.
    ANNALS OF NEUROLOGY, 2021, 90 : S160 - S160
  • [7] LINKAGE ANALYSIS OF NEURONAL CEROID LIPOFUSCINOSIS - REFINED MAPPING OF CLN3 AND EVIDENCE OF LOCUS HETEROGENEITY OF CLN3 AND CLN2
    MITCHISON, HM
    WILLIAMS, RE
    MCKAY, TR
    CALLEN, DF
    THOMPSON, A
    MULLEY, JC
    STALLINGS, RL
    HILDEBRAND, CE
    MOYZIS, RK
    JARVELA, I
    PELTONEN, L
    HAINES, J
    SUTHERLAND, GR
    GARDINER, RM
    CYTOGENETICS AND CELL GENETICS, 1992, 60 (3-4): : 173 - 173
  • [8] Diagnostic Confidence for CLN3 Disease (Juvenile Batten Disease)
    Masten, Margaux C.
    Vierhile, Amy
    Vermilion, Jennifer
    Adams, Heather R.
    Zimmerman, Grace A.
    Corre, Camille
    Augustine, Erika F.
    Mink, Jonathan W.
    NEUROLOGY, 2021, 96 (15)
  • [9] Neural acid extraneural expression of the neuronal ceroid lipofuscinoses genes CLN1, CLN2, and CLN3:: Functional implications for CLN3
    Chattopadhyay, S
    Pearce, DA
    MOLECULAR GENETICS AND METABOLISM, 2000, 71 (1-2) : 207 - 211
  • [10] BATTEN-DISEASE .2. GENOMIC ALTERATIONS IN CLN3
    TASCHNER, PEM
    MITCHISON, HM
    KREMMIDIOTIS, G
    ORAWE, A
    MUNROE, PB
    DEVOS, N
    BOUSTANY, RM
    LENSINK, I
    MEINCKE, LJ
    ANDERSON, JW
    DARIGO, KL
    JARVELA, IE
    BUCKLER, AJ
    GUSELLA, JF
    HAINES, JL
    GARDINER, RM
    SUTHERLAND, GR
    DOGGETT, NA
    CALLEN, DF
    MOLE, SE
    LERNER, TJ
    BREUNING, MH
    AMERICAN JOURNAL OF HUMAN GENETICS, 1995, 57 (04) : 1328 - 1328